Fig. 5: The prevalence of immune sera targeting known epitopes of human survivor mAbs are different between MARV and RAVV mRNA recipients.

BLI-based competition-binding assay in which mAbs compete with day 54 pre-infection serum antibodies from (A) MARV (n = 5) or (B) RAVV (n = 5) vaccine recipients for a specific epitope on biotinylated (A) MARV or (B) RAVV GPs immobilized on streptavidin sensors. The level of inhibition was determined as a percentage of blocking activity relative to mock-control sera against the tested mAb. Area under the curve (AUC) of normalized binding inhibition values calculated from a dilution series of each serum sample. Symbols indicate individual guinea pigs. Bars denote the average blocking of RBD mAbs (gold) or wing domain mAbs (purple) by sera from vaccinated groups ± SEM. Significance measured by one-way ANOVA with Tukey’s correction for multiple comparisons between the serum prevalence towards different mAb epitopes.